Ontosight® – Biweekly NewsletterJune 17th – June 30th, 2024 –Read More
Ontosight® Newsletter Issue 3
Blockchain and AI-based Platform iPlexus to Revolutionize Drug Discovery
Innoplexus AG announced a revolutionary update is coming soon to their iPlexus platform that will harness the power of blockchain technology and artificial intelligence to weed out wastefulness in early-stage drug discovery. iPlexus is a one-stop deep data ocean of relevant information for the pharmaceutical industry. It uses the power of Blockchain and AI to revolutionize the drug discovery and research process.
Co-founder and CEO of Innoplexus AG, Gunjan Bhardwaj, explained more about their vision for the new iPlexus, “Our mission at Innoplexus is to democratize the drug discovery process. We believe that cutting-edge technologies like AI and blockchain are the key to making this possible. After over 6 months of research, we believe that the new iPlexus is a major step forward for the preclinical trial industry and will solve many of the problems that are slowing the industry down. By overcoming these challenges, we will make drug discovery more efficient and bring down the consumer price of drugs.”
The launch date is scheduled for June 30, 2018. Blockchain and AI-based iPlexus intends to overcome data silos to make drug discovery more efficient. iPlexus will help in intelligence and insights throughout pre-clinical, clinical, regulatory and commercial phases of drug development in a quick, crisp and summarized snapshot with various profound dive opportunities.
The platform has the potential to bolster the healthcare system through practical innovation acceleration and equal opportunities. It would incentivize smaller researchers to share even failed experimental data. Data enrichment would, in turn, lead to data innovation and the innovation dynamics would be beneficial for the patients.
The original article was published on BCFocus.
Featured News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
